United States-based global pharmaceutical company MSD said on Monday that China's National Medical Products Administration has approved the use of multiple new indications of Gardasil®9, its ...

MSD's Gardasil®9, a nine-valent HPV vaccine, is approved for use in males between 16 and 26 years old by China's National Medical Products Administration on Monday. [Photo provided to chinadaily ...

MSD obtains a Non-Exclusive License for Cyprumed’s delivery technology to develop oral peptide therapeutics Cyprumed will be eligible to receive up to $493 million in upfront, development ...

MSD has fleshed out its cardiovascular disease pipeline by licensing an oral Lp(a) inhibitor from China's Jiangsu Hengrui Pharma for $200 million upfront. The deal gives MSD exclusive rights to ...

MSD and Moderna have kicked off another phase 3 trial of their personalised cancer vaccine V940 used alongside MSD's PD-1 inhibitor Keytruda, this time focusing on patients with earlier-stage non ...